PubRank

Mark J Sculpher

Author PubWeight™ 45.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med 2010 7.83
2 Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005 4.40
3 Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA 2002 3.42
4 Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008 3.33
5 Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006 2.59
6 The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS 2008 1.81
7 Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012 1.81
8 Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). Eur J Pain 2008 1.76
9 Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health 2012 1.76
10 Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011 1.73
11 Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ 2009 1.72
12 Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ 2011 1.42
13 Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). J Am Coll Cardiol 2005 1.31
14 Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005 1.30
15 A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep Med Rev 2009 1.20
16 Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence. Int J Technol Assess Health Care 2011 0.89
17 A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG 2003 0.88
18 The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments. Pharmacoeconomics 2010 0.88
19 Using value of information analysis to inform publicly funded research priorities. Appl Health Econ Health Policy 2005 0.86
20 Identifying research priorities: the value of information associated with repeat screening for age-related macular degeneration. Med Decis Making 2008 0.85
21 An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. Int J Technol Assess Health Care 2009 0.84
22 Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. Value Health 2009 0.83
23 Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis. Pharmacoeconomics 2006 0.82
24 Opportunities for improving the efficiency of paediatric HIV treatment programmes. AIDS 2015 0.79
25 An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? Eur J Health Econ 2009 0.79
26 Costs of an early intervention versus a conservative strategy in acute coronary syndrome. Int J Cardiol 2007 0.78
27 Unfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004). Med Decis Making 2004 0.75
28 The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). Value Health 2011 0.75
29 Better analysis for better decisions: facing up to the challenges. Pharmacoeconomics 2006 0.75